Lycopene
CAS 502-65-8
Lycopene (CAS 502-65-8) is a Phase 3 pharmaceutical compound with 3 bioactivity targets and 154 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 28871.21212121212 nM | 66 | - |
| - | Potency | 28321.923076923078 nM | 13 | - |
| - | IC50 | 6266.666666666667 nM | 3 | - |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| LYCOPENE | 29008 | SU | MTHSPL |
| lycopene | 29008 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Lycopene used for in pharmaceutical contexts?
Lycopene (CAS 502-65-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Lycopene?
Lycopene has 154 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Arthritis, Asthma, Asthma-chronic obstructive pulmonary disease overlap syndrome, Blood bilirubin increased, Breast cancer metastatic. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Lycopene also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Lycopene Cosmetic with EU status "permitted".
What clinical phase is Lycopene in?
Lycopene is rendered with ChEMBL max phase 3.